What is the current stock price of BiomX Inc. (PHGE)?

As of the latest market data, BiomX Inc. (PHGE) is trading at $2.89. The stock has seen a loss of -3.34% today.

Does BiomX Inc. (PHGE) pay a dividend?

Based on current data, BiomX Inc. does not have a confirmed active dividend policy.

What is the market cap of BiomX Inc.?

The current market capitalization of BiomX Inc. (PHGE) is approximately unavailable.

PHGE

BiomX Inc.·Healthcare

2.89

3.344%(−0.10)

Market Closed

3.07

6.228%(+0.18)

After Hours

Last Updated: — ET

52W L: $1.5052W H: $14.71

PHGE NEWS

seekingalpha.com

1d ago

BiomX Inc. (PHGE) Shareholder/Analyst Call Prepared Remarks Transcript

globenewswire.com

1d ago

BiomX Acquires Zorronet, Autonomous AI Command-and-Control Platform for Real-Time Defense and Security Applications

Targets $81B command-and-control and video analytics markets by 2030, driven by real-time situational awareness in defense environments Targets $81B command-and-control and video analytics markets by 2030, driven by real-time situational awareness in defense environments

globenewswire.com

Mar 31

BiomX Obtains Option to Acquire Control of Israeli Laser-Radar Counter-Drone System

The platform delivers ~99% accuracy in real-world deployments across defense and infrastructure; When closed, the transaction value is estimated at approximately $45 million The platform delivers ~99% accuracy in real-world deployments across defense and infrastructure; When closed, the transaction value is estimated at approximately $45 million

globenewswire.com

Mar 30

BiomX Adds Former Mossad Deputy to Advisory Board

Dr. Ehud (Udi) Levi brings decades of intelligence experience as Company evaluates expansion into security, defense, and counter-UAS technologies Dr. Ehud (Udi) Levi brings decades of intelligence experience as Company evaluates expansion into security, defense, and counter-UAS technologies

globenewswire.com

Mar 27

BiomX Inc. Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency

Discloses “Going Concern” Explanatory Paragraph in Auditor's Report Discloses “Going Concern” Explanatory Paragraph in Auditor's Report

globenewswire.com

Mar 26

BiomX Launches Security Subsidiary in Israel and Will Initially Invest Over $3 million In Its Operations

Initiative marks entry into Israel's rapidly growing autonomous AI defense, firefighting and first response activities Initiative marks entry into Israel's rapidly growing autonomous AI defense, firefighting and first response activities

Company Profile

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2019-03-13

Beta

1.70

Websitewww.biomx.com↗